Academic Journal
View in EDS

Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Bibliographic Details
Title: Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
Authors: Layman, Rachel M *, Han, Hyo S, Rugo, Hope S, Stringer-Reasor, Erica M, Specht, Jennifer M, Dees, E Claire, Kabos, Peter, Suzuki, Samuel, Mutka, Sarah C, Sullivan, Brian F, Gorbatchevsky, Igor, Wesolowski, Robert
Source: In The Lancet Oncology April 2024 25(4):474-487
Database: ScienceDirect
More Details
ISSN:14702045
DOI:10.1016/S1470-2045(24)00034-2
Published in:The Lancet Oncology
Language:English